GALDERMA Committed to the future of Dermatology Read more ...
Talent Working at GaldermaRead more ...
FOCUSED Patients at the heart of everything we doRead more ...
PARTNER With Healthcare Professionals around the WorldRead more ...
You are here » News
This market authorisation is part of a process including 15 countries in Europe. Azzalure ® will be commercialised in Spain by Galderma. Lausa...
Read more...
Posted in: Press release
This market authorisation is part of a process including 15 countries in Europe. Azzalure ® will be commercialised in Germany by Galderma Laus...
Lausanne (Switzerland) and Paris (France), 30 March 2009 – Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an ...
First market authorisation of 15 for Azzalure ® in Europe Azzalure ® will be commercialised by Galderma Lausanne (Switzerland) and Paris (Fran...
Fort Worth, TX – February 3, 2009 – Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Vectical™ (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults.
Follow us
Growing a responsible dermatological community
Discover some of the positive initiatives we are involved in across the world
We are committed
